Healthcare ❯ Pharmaceutical Industry

Drug Development

Clinical Trials Research and Development Obesity Treatments Market Trends GLP-1 Medications Innovation AI in Healthcare FDA Approval Cancer Drugs Monoclonal Antibodies Research Funding ALS Treatment Regulatory Approval Mental Health Treatments Cancer Therapies Cancer Medicines Pricing Strategies Clinical Efficacy Immunological Treatments Weight Management Drugs Pricing Policies Market Strategy Weight Loss Drugs Biologics Sustainability Long-Acting Injectables Compounding Pharmacy Biopharmaceuticals Obesity Treatment Diabetes Treatment Market Competition Market Access Investigational Drugs Weight-loss Medications Antiviral Drugs Oncology Drugs Antibiotics Covid-19 Vaccines Regulatory Compliance Cancer Treatments Efficacy Studies Weight Loss Medications

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

State incentives worth up to $105 million helped secure the site to boost U.S. capacity.

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Teva’s Olanzapine LAI Shows No PDSS in Phase 3 SOLARIS Long-Term Data Presented at Psych Congress

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030